Nu-Med Plus (NUMD) Free Cash Flow Growth (3y) (2015 - 2025)
Nu-Med Plus (NUMD) Free Cash Flow Growth (3y) (2015 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.71 Bn | 194.11 Bn | 7.27 Bn | 41.96% |
| 2 | Stryker | 127.04 Bn | 123.56 Bn | 4.50 Bn | 25.48% |
| 3 | Medtronic | 118.81 Bn | 109.59 Bn | 6.41 Bn | 0.05% |
| 4 | Boston Scientific | 73.18 Bn | 72.64 Bn | 3.85 Bn | 35.42% |
| 5 | Edwards Lifesciences | 52.03 Bn | 47.78 Bn | 1.35 Bn | 250.09% |
| 6 | Dexcom | 34.34 Bn | 32.39 Bn | 830.00 Mn | 12.01% |
| 7 | GE HealthCare Technologies | 33.78 Bn | 31.67 Bn | 2.18 Bn | 35.65% |
| 8 | Koninklijke Philips | 26.35 Bn | 23.03 Bn | 4.55 Bn | 20.87% |
| 9 | Steris | 23.03 Bn | 22.54 Bn | 684.20 Mn | 9.23% |
| 10 | Nu-Med Plus | 2.03 Mn | 2.02 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -12.79% |
| Sep 30, 2025 | -172.24% |
| Dec 31, 2024 | 56.43% |
| Jun 30, 2024 | 67.34% |
| Mar 31, 2024 | 82.16% |
| Dec 31, 2023 | 60.83% |
| Sep 30, 2023 | 42.84% |
| Jun 30, 2023 | 46.10% |
| Mar 31, 2023 | 40.39% |
| Dec 31, 2022 | 41.91% |
| Sep 30, 2022 | 26.17% |
| Jun 30, 2022 | 72.39% |
| Mar 31, 2022 | 63.36% |
| Dec 31, 2021 | 47.99% |
| Sep 30, 2021 | 34.05% |
| Jun 30, 2021 | 12.61% |
| Mar 31, 2021 | 1.04% |
| Dec 31, 2020 | 20.00% |
| Sep 30, 2020 | 7.55% |
| Jun 30, 2020 | -18.03% |